Endocrine therapy and CDK4/6 inhibition are the standard-of-care treatments for patients with advanced or metastatic estrogen receptor-positive (ER+) breast cancer. Despite improvements in the overall progression-free survival, resistance develops in patients by unidentified mechanisms. Preliminary CRISPR/Cas9 screens from the Caldon lab revealed that loss of the MAPK9 gene (encoding JNK2) …
This report summarizes a total of 2 months of internship project at the Faculty of Science, Mahidol University, Thailand. This internship project takes place in the science department more specifically in the organic chemistry laboratory. During this internship, the authors tried to synthesize and investigate the intermediates of kusunokinin to enhance its anticancer activity. Kusunokinin inter…
Estrogen receptor-positive (ER+) breast cancer accounts for 67-80% of all breast cancer subtypes. Endocrine therapies are initially given as part of first-line treatment, however 20% of the patients develop resistance. The overactivation of cyclin dependent kinase 4/6 (CDK4/6) is one of the underlying mechanisms. Hence the addition of CDK4/6 inhibitors such as palbociclib in combination with en…
Breast cancer is one of the most commonly found cancer cases worldwide with a relatively high mortality rate. It was found to be highly correlated with metastasis properties of cancer cells that facilitate their rapid invasion and motility. The reduction of disulfide bonds into active thiol functional groups was previously found to be able to reduce the migration and invasion of other cancer…
In 2020, breast cancer incidence in Indonesian women had become the highest among other cancers. There are different approaches to combat this disease; one of them is immunotherapy which focuses on utilizing the body’s immune cells to eliminate and evoke an immune response against cancer. This study aims to develop a multi-epitope peptide-based vaccine targeting Mucin 1 (MUC-1) and Matrix Met…